Chemoinformaics analysis of Terbutylazine-2-hydroxy
| Molecular Weight | 211.269 | nRot | 3 |
| Heavy Atom Molecular Weight | 194.133 | nRig | 9 |
| Exact Molecular Weight | 211.143 | nRing | 1 |
| Solubility: LogS | -2.109 | nHRing | 1 |
| Solubility: LogP | 0.819 | No. of Aliphatic Rings | 0 |
| Acid Count | 0 | No. of Aromatic Rings | 1 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 0 |
| Atoms Count | 32 | No. of Aliphatic Hetero Cycles | 0 |
| No. of Heavy Atom | 15 | No. of Aromatic Carbocycles | 0 |
| nHetero | 6 | No. of Aromatic Hetero Cycles | 1 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 17 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 9 | No. of Saturated Rings | 0 |
| No. of Nitrogen atom | 5 | No. of Arom Atom | 6 |
| No. of Oxygen atom | 1 | No. of Arom Bond | 6 |
| nHA | 5 | APOL | 32.6675 |
| nHD | 3 | BPOL | 21.9125 |
| QED | 0.582 |
| Synth | 4.047 |
| Natural Product Likeliness | -0.508 |
| NR-PPAR-gamma | 0.001 |
| Lipinski | Accepted |
| Pfizer | Accepted |
| GSK | Accepted |
| Golden Triangle | Accepted |
| Pgp-inh | 0 |
| Pgp-sub | 0.871 |
| HIA | 1 |
| CACO-2 | -4.217 |
| MDCK | 0.000107324 |
| BBB | 0.855 |
| PPB | 0.142401 |
| VDSS | 0.994 |
| FU | 0.668785 |
| CYP1A2-inh | 0.018 |
| CYP1A2-sub | 0.966 |
| CYP2c19-inh | 0.05 |
| CYP2c19-sub | 0.039 |
| CYP2c9-inh | 0.001 |
| CYP2c9-sub | 0.017 |
| CYP2d6-inh | 0 |
| CYP2d6-sub | 0 |
| CYP3a4-inh | 0.023 |
| CYP3a4-sub | 0.939 |
| CL | 6.601 |
| T12 | 0.926 |
| hERG | 0.641 |
| Ames | 0.101 |
| ROA | 0.359 |
| SkinSen | 0.945 |
| Carcinogencity | 0.952 |
| EI | 0.246 |
| Respiratory | 0.977 |
| NR-Aromatase | 0.001 |
| Antiviral | No |
| Prediction | 0.870154 |